Journal of Medical Microbiology (2011), **60**, 397–407 DOI 10.1099/jmm.0.023051-0

Review

Antibiotic resistance mechanisms of *Vibrio cholerae*

Maya Kitaoka, Sarah T. Miyata, Daniel Unterweger and Stefan Pukatzki

Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Alberta, Canada

Correspondence
Stefan Pukatzki
spukatzki@ualberta.ca

As the causative agent of cholera, the bacterium *Vibrio cholerae* represents an enormous public health burden, especially in developing countries around the world. Cholera is a self-limiting illness; however, antibiotics are commonly administered as part of the treatment regimen. Here we review the initial identification and subsequent evolution of antibiotic-resistant strains of *V. cholerae*. Antibiotic resistance mechanisms, including efflux pumps, spontaneous chromosomal mutation, conjugative plasmids, SXT elements and integrons, are also discussed. Numerous multidrug-resistant strains of *V. cholerae* have been isolated from both clinical and environmental settings, indicating that antibiotic use has to be restricted and alternative methods for treating cholera have to be implemented.

Introduction

The acute diarrhoeal disease cholera is responsible for approximately 120 000 deaths every year and has a major impact on the health of young children between the ages of 1 and 5 years (WHO, 1995). Cholera is contracted by ingestion of food or water contaminated with the Gram-negative bacterium *Vibrio cholerae*. The bacteria pass through the human gastric acid barrier into the small intestine where they colonize, multiply and begin to secrete cholera toxin. Because this organism is sensitive to the low pH found in the human stomach, a high infectious dose of $\sim 10^8$ bacteria is required for the onset of severe cholera; however, the infectious dose can drop to $\sim 10^4$ bacteria in individuals who produce less stomach acid, including young children, the elderly and those who take antacids (Cash *et al.*, 1974). About 1–5 days after ingestion, cholera patients experience sudden watery diarrhoea and vomiting. Up to 20 litres of watery diarrhoea, referred to as rice-water stool, are shed daily containing 10^9 *V. cholerae* per millilitre of stool (Dizon *et al.*, 1967). Water loss caused by cholera may reach one litre per hour in adults, leading to severe dehydration, shock and eventual death (Sack *et al.*, 2004). If left untreated, the cholera fatality rate reaches 50 % within a few hours to days after onset of the disease (Maier & Pepper, 2009).

V. cholerae utilizes two virulence factors, the toxin coregulated pilus (TCP) and cholera toxin. TCP, encoded in the *Vibrio* pathogenicity island I (VPI I), is a type IV pilus that allows the organism to aggregate (Kirn *et al.*, 2000) – a mechanism that protects individual cells from shearing forces in the small intestine. TCP is also essential for *V. cholerae* colonization of the small intestine of infant mice (Taylor *et al.*, 1987) and humans (Herrington *et al.*, 1988). Once the small intestine is successfully colonized, *V. cholerae* cells secrete cholera toxin. The toxin activates the cystic fibrosis transmembrane conductance regulator (CFTR) in the epithelial cells that line the small intestine, leading to massive fluid efflux into the lumen of the small intestine.

Over 200 *V. cholerae* O-antigen serogroups have been identified (Shimada *et al.*, 1994). With the exception of O139 (Siddique *et al.*, 1996), strains of the O1 serogroup have been responsible for all of the major cholera pandemics recorded so far. O1 strains are further classified into 'classical' and 'El Tor' biotypes based on phenotypic characteristics (listed in Table 1) and defined genotypic differences (Safa *et al.*, 2010).

The first six recorded cholera pandemics (1899–1923) have been attributed to classical strains (Safa *et al.*, 2010), while El Tor strains are responsible for the current seventh pandemic, which started in 1961 in Indonesia (Colwell, 1996). In the early 1990s, around the same time as the O139 strain emerged, new variants of *V. cholerae* O1

Table 1. Phenotypic differences between *V. cholerae* classical and El Tor O1 strains

A number of tests can be used to distinguish biotypes, including haemolysis of sheep erythrocytes, agglutination of chicken erythrocytes, the Voges–Proskauer reaction (detects the presence of acetoin in bacterial cultures) and sensitivity to polymyxin B and to specific bacteriophages. +, Positive; −, negative; s, sensitive; r, resistant.

Test	Classical	El Tor
Haemolysis of sheep erythrocytes	−	+
Agglutination of chicken erythrocytes	−	+
Voges–Proskauer reaction	−	+
Polymyxin B resistance	s	r
Phage IV	s	r
Phage 5	r	s

Downloaded from www.sgmjournals.org by
IP: 93.91.26.97
On: Sun, 05 Jul 2015 21:04:05

appeared carrying both classical and El Tor biotype traits (hybrid strains) (reviewed by Safa *et al.*, 2010).

All *V. cholerae* serogroups can be found in aquatic environments such as estuaries and brackish waters (Kaper *et al.*, 1979) as either free-living cells or associated with other aquatic organisms such as copepods (Huq *et al.*, 1983). Upon nutrition deprivation (likely to be encountered in aquatic environments), *V. cholerae* switches to a viable-but-nonculturable form which cannot be grown under standard culturing conditions. Quiescent *V. cholerae* reverts back to the infectious, transmissible state when the organism encounters favourable conditions (Binsztein *et al.*, 2004). Quiescence is believed to contribute to the persistence of *V. cholerae* in aquatic environments between cholera epidemics (Reidl & Klose, 2002). Genetic exchange between *V. cholerae* and other bacteria or viruses is responsible for the emergence of toxigenic strains (Mekalanos *et al.*, 1997; Faruque *et al.*, 2005).

Why use antibiotics?

V. cholerae does not typically cause systemic infection. Antibiotics are not required to resolve cholera symptoms and cannot be used as a sole treatment for the disease; however, there are advantages to combining oral rehydration therapy with antibiotic treatment (antibiotics discussed here are listed in Table 2). Antibiotics are administered to lessen the duration of illness by approximately 50 % and to reduce shedding of *V. cholerae* in the stool (Greenough *et al.*, 1964; Lindenbaum *et al.*, 1967; Pierce *et al.*, 1968). Antibiotics reduce the severity of symptoms by decreasing the volume of diarrhoea, and thus the amount of fluids required to maintain hydration (Greenough *et al.*, 1964; Lindenbaum *et al.*, 1967; Pierce *et al.*, 1968). This is especially important in developing countries where access to safe drinking water is limited and oral rehydration solutions are in short supply.

For the treatment of cholera, an oral or intravenously administered solution containing glucose, sodium chloride, potassium chloride and trisodium citrate can save a patient from dehydration (WHO, 2002). The antibiotics tetracycline and quinolones have been widely used (Mhalu *et al.*, 1979; Towner *et al.*, 1980) to reduce the symptoms of cholera, but the emergence of *V. cholerae* strains resistant to antibiotics has restricted their use to patients with severe dehydration (Garg *et al.*, 2001). In severe cases, a single dose of doxycycline (a member of the tetracycline antibiotics group) co-administered with fluid replacement therapy is usually sufficient to stabilize the patient. Alternatively, a multidose treatment of tetracycline can be administered; in the case of young children, liquid erythromycin is preferred (WHO, 2004). In a randomized clinical trial, erythromycin yielded the best clinical recovery rates in children (Roy *et al.*, 1998).

Table 2. Antibiotics (discussed in this review) and their mode of action

Information collected from Katzung *et al.* (2009), except for alafosfalin (Atherton *et al.*, 1979).

Mechanism	Class	Compounds	Bacterial target
Cell growth inhibitors	β-Lactam antibiotics	Penicillin, ampicillin	Penicillin-binding protein
	Glycopeptide	Vancomycin	Nascent peptidoglycan
	Phosphonopeptides	Alafosfalin	Alanine racemase
Protein synthesis inhibitors	Macrolides	Erythromycin	50S subunit of the ribosome
	Chloramphenicol	–	50S subunit of the ribosome
	Aminoglycosides	Streptomycin, kanamycin, gentamicin	30S subunit of the ribosome
	Spectinomycin		30S subunit of the ribosome
	Tetracyclines	Tetracycline, doxycycline	30S subunit of the ribosome
	Oxazolidinones	Linezolid	23S subunit of the ribosome
	Rifampicin		β-Subunit of RNA polymerase
Folic acid metabolism inhibitors	Sulfonamide	Sulfamethoxazole	Dihydropteroate synthase
	Trimethoprim		Dihydrofolic acid reductase
DNA replication inhibitors	(Fluoro)quinolones	Ciprofloxacin, nalidixic acid, norfloxacin	Topoisomerase II (DNA gyrase); topoisomerase IV
Inducers of cell lysis/cytotoxicity	Polymyxins	Polymyxin B	Cell membrane
	Anthracyclines	Doxorubicin	Inhibition of topoisomerase II; binding to DNA and membranes; generation of toxic radicals

Downloaded from www.sgmjournals.org by
IP: 93.91.26.97
On: Sun, 05 Jul 2015 21:04:05

Though there are obvious benefits to individuals who are treated with antibiotics, the World Health Organization does not recommend their general use because antibiotics contribute to increasing antimicrobial resistance, making cholera and other bacterial infections more difficult to treat (Glass *et al.*, 1980; Hedges & Jacob, 1975; Sack *et al.*, 2001; Threlfall & Rowe, 1982). Use of antibiotics to treat cholera should be strictly relegated to patients suffering from severe dehydration.

Mechanisms of antibiotic resistance

V. cholerae becomes drug resistant by exporting drugs through efflux pumps, chromosomal mutations or developing genetic resistance via the exchange of conjugative plasmids, conjugative transposons, integrons or self-transmissible chromosomally integrating SXT elements. Infections caused by antibiotic-resistant *V. cholerae* from 2000 to 2010 are listed in Table 3.

Bacterial efflux pumps

V. cholerae uses multidrug efflux pumps to export a broad range of antibiotics, detergents and dyes that are chemically and structurally unrelated (Paulsen *et al.*, 1996). The two major groups of *V. cholerae* efflux pumps are distinguished by their energy sources: ATP hydrolysis, or the proton-motive force (PMF) of transmembrane H^+ or Na^+ gradients (Putman *et al.*, 2000). PMF pump families include MATE (multidrug and toxic compound extrusion), MFS (major facilitator superfamily), RND (resistance–nodulation–cell division) and SMR (small multidrug resistance) (Paulsen *et al.*, 1996). One of the few bacterial ATP-driven pumps is VcaM, a *V. cholerae*



Fig. 1. Important historical events related to *Vibrio cholerae* and the pandemics. Key breakthroughs in the field are listed on the left side of the bar. Pandemics are indicated as coloured columns with the responsible serogroups indicated within. Selected outbreaks are listed on the right side of the figure. Photographs are public domain according to the 'Images from the History of Medicine (IHM)' and Wikimedia Commons.

Downloaded from www.sgmjournals.org by
IP: 93.91.26.97
On: Sun, 05 Jul 2015 21:04:05

Table 3. Major drug-resistant *V. cholerae* strains reported in the last decade

Numbers in parentheses indicate the percentage of *V. cholerae* isolates with antibiotic resistance. ND, Not determined; Amo, amoxicillin; Amp, ampicillin; Cm, chloramphenicol; Co, cotrimoxazole; Cpr, ciprofloxacin; Dox, doxycycline; Ery, erythromycin; FQ, fluoroquinolone; Fz, furazolidone; Gent, gentamicin; Kan, kanamycin; NA, nalidixic acid; Neo, neomycin; Nf, norfloxacin; PB, polymyxin B; Qu, quinolone; Sm, streptomycin; Spec, spectinomycin; SXT, sulfamethoxazole–trimethoprim; Su, sulphonamides; Tet, tetracycline; Tri, trimethoprim; Vanc, vancomycin.

Year	Country	Strain	Antibiotic resistance	Mechanism	Reference
1993–2005	Pakistan	O1 Inaba/Ogawa	Co (100), Cm (3)	ND	Jabeen *et al.* (2008)
1995–2001	Indonesia	O1/non-O1	Amp, SXT, Cm, Tet	ND	Tjaniadi *et al.* (2003)
1995, 2000, 2002	Vietnam	O1	1995: Sm 2000: SXT, Sm 2002: –	1995: class I integron. *aadA1* 2000: SXT element, *strAB* 2002: –	Ehara *et al.* (2004)
Jan 1999–Dec 2007	India	O1 El Tor Ogawa	Fz, Cpr, Amo, Co	ND	Chander *et al.* (2009)
2000–2004	Hubli, India	O1, O139 Non-O1/non-O139	FQ (since 2002)	ND	Chandrasekhar *et al.* (2008)
2000	Madagascar	ND	Co, Sm, Cm, Amp, Tet	26 kb self-transmissible plasmid	Rakoto Alson *et al.* (2001)
May–Jun 2000	India	O1 El Tor Ogawa O139	Fz	ND	Samal *et al.* (2001)
2002–2008	Bangladesh	O1	Cpr	*qnrVC3* encoded on SXT element protects topoisomerase from quinolone	Kim *et al.* (2010)
2002	Hubli, India	O1 El Tor Ogawa O139 Non-O1/non-O139	O1 Ogawa: Amp (62.5), Co (81.3), NA (93.8) O139: Amp (100), Gent (54.5), Tet (54.5), NA (100) Non-O1/non-O139: Amp (82.4), Co (61.8), NA (94.1)	ND	Krishna *et al.* (2006)
2001–2006	East Delhi, India	O1 El Tor Ogawa/Inaba	NA, Co	ND	Das *et al.* (2008)
Nov 2002–Apr 2004	Mozambique	O1 El Tor Ogawa	Cm (57.9), Co (96.6), Tet (97.3), Qu (4.2)	ND	Mandomando *et al.* (2007)
2003	Thua Thien, Vietnam	O1	Amo, Ery	ICE	Bani *et al.* (2007)
Sep 2004–Jun 2005	Dhaka, Bangladesh	O1	SXT, Tet, Ery, Sm	SXT element	Faruque *et al.* (2006)
2004	Hangzhou, East China	O139	Amp, Sm, Gent, Tet, Cm, SXT	pMRV150; pIP1202-like plasmid (IncA/C plasmid in MDR *Y. pestis*)	Pan *et al.* (2008)
2004	Chennai, India	O1 El Tor Ogawa (classical CTXΦ)	Co, NA, nitrofurantoin, Spec, Sm, SXT	Class I integron SXT element	Goel *et al.* (2010)

Downloaded from www.sgmjournals.org by
IP: 93.91.26.97
On: Sun, 05 Jul 2015 21:04:05

Table 3. cont.

Year	Country	Strain	Antibiotic resistance	Mechanism	Reference
2004–2006	Iran	ND	SXT, Sm, Cm	SXT element	Adabi *et al.* (2009)
Oct 2004–Mar 2006	Senegal	O1 El Tor	Co (90.3)	ND	Manga *et al.* (2008)
2004–2005	Cameroon	O1	SXT (100), Amp	ND	Ngandjio *et al.* (2009)
Oct 2004–Dec 2005	Dhaka and Matlab, Bangladesh	O1 Ogawa and Inaba	Dhaka: Tet (55), Ery (44), SXT (99), Fz (100) Matlab: Tet (54), Ery (48), Ery (97), Fz (100)	ND	Faruque *et al.* (2007)
2005	Iran	O1 El Tor Inaba	Nf (97), Cpr (92), Kan (88), amikacin (85), Tet (77), Dox (67), Fz (100), SXT (98), Ery (62)	ND	Keramat *et al.* (2008)
Aug 2006–Sep 2008	North-west Ethiopia	O1 Inaba	Co (100), Cm (94), Amp (89), Ery (15), Tet (6.2), Cpr (1.2)	ND	Abera *et al.* (2010)
2006	Accra, Ghana	O1	SXT	SXT element (88.9) Class 2 integron (81.5) Class 1 integron (7.4)	Opintan *et al.* (2008)
Dec 2006–Feb 2007	Namibia	O1 El Tor Inaba	SXT, Sm	ND	Smith *et al.* (2008)
Aug–Sep 2007	India	O1 El Tor	Amp, co-amoxiclav, aztreonam, Co, Ery, metronidazole, NA, Neo, nitrofurantoin, oxacillin, PB, Spe, Sm, Tri, Vanc	Class 1 integron SXT element	Jain *et al.* (2008)
2008	Iran	O1 El Tor Inaba Non-agglutinating (NAG) strains	Inaba: NA (100), Amo (100), SXT (95.7), Fz (91.3) NAG: Ery (77.4)		Ranjbar *et al.* (2010)
Jun 2008–Jan 2009	Nepal	O1 El Tor Ogawa	Fz (100), NA, Co	ND	Karki *et al.* (2010)
Jan 2009	Zimbabwe	O1 El Tor Ogawa and Inaba	Fz, SXT	ND	Islam *et al.* (2009)

ABC (ATP-binding cassette) multidrug resistance efflux pump. VcaM confers resistance to structurally divergent drugs (e.g. tetracycline, norfloxacin, ciprofloxacin and doxorubicin).

V. cholerae uses an array of MATE-family efflux systems, namely VcmB, VcmD, VcmH, VcmN, VcmA and VcrM (Begum *et al.*, 2005; Huda *et al.*, 2003). In addition, the *V. cholerae* O1 El Tor N16961 genome carries a homologue of NorM in *Vibrio parahaemolyticus* (Heidelberg *et al.*, 2000) that mediates resistance to hydrophilic fluoroquinolones, aminoglycosides and norfloxacin (Morita *et al.*, 1998; Singh *et al.*, 2006).

MFS transporters in *V. cholerae* include the *V. cholerae* efflux systems (Colmer *et al.*, 1998) that confer resistance to bile (deoxycholate), antibiotics (e.g. chloramphenicol and nalidixic acid) and the proton gradient-uncoupling agent carbonyl cyanide *m*-chlorophenylhydrazone (Colmer *et al.*, 1998; Woolley *et al.*, 2005). It was recently shown that the classical O395 strain carries the MFS efflux protein EmrD-3, which confers resistance to linezolid, rifampicin, erythromycin and chloramphenicol when expressed in a drug-hypersensitive *Escherichia coli* strain (Smith *et al.*, 2009). The EmrD-3 gene is also present in the genome of the El Tor strain N16961 and the non-O1/non-O139 strains V51, V52 and TMA 21 (M. Kitaoka, unpublished observation).

The *V. cholerae* RND efflux systems are encoded by six operons (*vexRAB*, *vexCD*, *vexEF*, *vexGH*, *vexIJK* and *vexLM*) (Bina *et al.*, 2006, 2008) and exhibit particularly broad substrate specificity (Van Bambeke *et al.*, 2003).

Downloaded from www.sgmjournals.org by
IP: 93.91.26.97
On: Sun, 05 Jul 2015 21:04:05

Interestingly, the *V. cholerae* RND systems play a role not only in the efflux of a variety of compounds (e.g. Triton X-100, SDS, polymyxin B, erythromycin, bile salts, penicillin), but also in colonization (Bina *et al.*, 2008). Collectively, these results indicate that efflux pumps are not employed exclusively for drug resistance, but also play a role in the expression of important virulence genes in *V. cholerae*.

Spontaneous mutations

Resistance to antimicrobial compounds can arise through spontaneous mutations in the bacterial chromosome. Mutations conferring resistance to the cell wall biosynthesis inhibitor alafosfalin and to the DNA replication inhibitor family of quinolones are well documented in *V. cholerae* (Allen *et al.*, 1979; Gellert *et al.*, 1977; Goss *et al.*, 1965; Sugino *et al.*, 1977). A comprehensive study during the 1980 cholera epidemic in the United Republic of Tanzania (Towner *et al.*, 1980) revealed that *V. cholerae* genes undergo higher mutation rates than *E. coli* genes, facilitating resistance to antibiotics such as alafosfalin (Atherton *et al.*, 1979). Studies with radiolabelled alafosfalin demonstrated that the mechanism of resistance involved impaired uptake of the drug; however, the chromosomal mutation leading to this resistance remains unknown (Towner *et al.*, 1980). In 2002, Baranwal and coworkers reported an increase in quinolone resistance in *V. cholerae* clinical isolates and conducted a study to determine the mechanism behind this resistance (Baranwal *et al.*, 2002). They found chromosomal mutations in the genes *gyrA* and *parC*, which encode subunits of DNA gyrase and topoisomerase IV, respectively. Presumably these mutations alter the affinity of DNA gyrase and topoisomerase IV for the antibiotic, and thus protect *V. cholerae* from quinolones. In 2010, Kim and coworkers conducted a retrospective study to determine mechanisms accounting for the increasing quinolone resistance observed in Dhaka Hospital in Bangladesh over a 6-year period from 2002 to 2008. Similar to the study by Baranwal *et al.* (2002), they found that *V. cholerae* had accumulated chromosomal mutations in the genes *gyrA* and *parC*, conferring increased resistance to quinolones (Kim *et al.*, 2010). It was noted that strains collected earlier in the 6-year period contained a mutation only in *gyrA* and, over time, these strains gained the additional mutation in *parC*, conferring higher levels of quinolone resistance. It appears that subjection of *V. cholerae* to quinolones during cholera treatments engendered increasing resistance to these antibiotics. A multitude of studies (Abera *et al.*, 2010; Das *et al.*, 2008; Islam *et al.*, 2009; Karki *et al.*, 2010; Ngandjio *et al.*, 2009; Ranjbar *et al.*, 2010; Roychowdhury *et al.*, 2008) have documented resistance of *V. cholerae* towards a variety of antibiotics commonly used to treat cholera (e.g. tetracycline, erythromycin, chloramphenicol, quinolones); however, these studies were designed to evaluate the antibiotic resistance of *V. cholerae* strains and not to elucidate mechanisms of resistance. As such, it is possible that spontaneous chromosomal mutations are responsible for resistance to any of the above named antimicrobial compounds.

SXT elements and integrons

The spread of antibiotic-resistant *V. cholerae* is also facilitated by horizontal gene transfer via self-transmissible mobile genetic elements, including SXT elements – mobile DNA elements belonging to the class of integrative conjugating elements (ICEs). The SXT element was first described in *V. cholerae* serogroup O139 based on its ability to harbour genes that provide the host bacterium with resistance to sulfamethoxazole, trimethoprim and streptomycin (Waldor *et al.*, 1996). Today, many strains of the O1 and O139 serogroups isolated around the globe have acquired SXT elements through natural spread (Hochhut *et al.*, 2001; Burrus *et al.*, 2006).

Similar to conjugative plasmids, ICEs are exchanged between two bacteria by conjugation; however, unlike plasmids, ICEs need to integrate into the chromosome to propagate since they do not have the capacity to replicate autonomously (Hochhut & Waldor, 1999). SXT elements integrate into the 5′-end of *prfC*, a chromosomal gene that encodes peptide chain release factor 3 (Hochhut & Waldor, 1999). Site-specific recombination between a segment of the circular ICE (*attP*) and the nearly identical chromosomal sequence (*attB*) is mediated by the SXT-encoded (integrase family) tyrosine recombinase Int (Hochhut & Waldor, 1999). Once integrated, the SXT element replicates with the host chromosome. Subsequent conjugation with other bacteria is enabled by interbacterial translocation through an apparatus encoded by genes in the SXT element that mediates transfer to a wide range of bacterial species, including clinical isolates of *Providencia alcalifaciens* (reviewed by Burrus *et al.*, 2006). The SXT element excises from the chromosome with the help of the directionality factor Xis and the integrase Int (Burrus & Waldor, 2003). SXT elements have been found with high frequency in numerous organisms since their discovery in 1996 (Waldor *et al.*, 1996). This is most likely the result of dispersal by horizontal gene transfer. Beaber *et al.* (2004) found that horizontal dissemination of SXT-encoded antibiotic resistance genes is regulated by the bacterial SOS response. These investigators elegantly demonstrated that stress alleviates the SXT-encoded repressor SetR, which in turn activates excision and conjugation of the element. Interestingly, ciprofloxacin acts as an inducing molecule, thus promoting horizontal transfer of SXT elements. This work suggests that antimicrobial agents can promote the spread of antibiotic resistance genes, contributing to the successful spread of SXT elements in the *V. cholerae* population. Despite their rapid spread, SXT elements are unstable and undergo rapid change. For example, an SXT element from a Laos *V. cholerae* isolate lost resistance to trimethoprim and gained genes encoding a putative exonuclease and helicase (Iwanaga *et al.*, 2004). Besides conferring antibiotic resistance, SXT

Downloaded from www.sgmjournals.org by
IP: 93.91.26.97
On: Sun, 05 Jul 2015 21:04:05

elements have the capacity to mobilize conjugative plasmids and genomic islands *in trans* (Daccord *et al.*, 2010; Hochhut *et al.*, 2000), providing alternative mechanisms for antibiotic resistance gene transfer.

Dissemination of antibiotic resistance genes is also facilitated when *V. cholerae* cells share mobile integrons with other bacterial cells. Integrons are genetic assembly platforms that incorporate exogenous open reading frames such as antibiotic resistance cassettes via site-specific recombination in a site proximal to a promoter that drives their expression. All *V. cholerae* isolates harbour large chromosomal integrons, giving them the capacity to rapidly transfer gene cassettes containing antibiotic resistance genes (Mazel, 2006). In addition, clinical and environmental *V. cholerae* can also contain mobile integrons, which are smaller (0–10 cassettes), but are embedded within mobile elements such as conjugative plasmids and transposons (Mazel, 2006) and can disseminate horizontally. Class 1 integrons are by far the most frequent type in this category and are closely associated with a Tn*402* transposon, whereas class 2 integrons are associated with a Tn*21* transposon. Both classes carry multiple gene cassettes encoding antibiotic resistance genes, such as *dfrA1* (trimethoprim resistance) (Dalsgaard *et al.*, 1999; Opintan *et al.*, 2008). The recombination activity of integrons (like SXT elements) is stimulated by the SOS response, which can be triggered by various antibiotics (Beaber *et al.*, 2004; Guerin *et al.*, 2009).

Conjugative plasmids

Because tetracyclines are oral antibiotics often given to patients during rehydration therapy (Greenough *et al.*, 1964), it is not surprising that many *V. cholerae* strains resistant to these drugs have been identified. One of the first reported tetracycline-resistant strains (exhibiting resistance to streptomycin, tetracycline and chloramphenicol) was isolated in the Astrakhan region of the USSR circa 1970 (Fig. 1). The resistance was transferable to *E. coli* K-12, and the strain was shown to carry a single plasmid (Hedges & Jacob, 1975). Similarly, a cholera outbreak in Matlab, Bangladesh, in 1979 was caused by a strain that carried a multiple-drug-resistant plasmid transferable through conjugation with other bacteria, including *E. coli* (Glass *et al.*, 1983). This plasmid conferred resistance to a number of antibiotics in addition to tetracycline, including ampicillin, kanamycin, streptomycin, gentamicin and trimethoprim. However, this multiple-drug-resistant strain disappeared from the area within a decade (Faruque *et al.*, 1998). Table 3 includes *V. cholerae* strains that have developed episomally propagated antibiotic resistance.

Conclusions

Antibiotics are often used in combination with rehydration therapy because they are believed to relieve the symptoms of cholera faster than rehydration treatment alone, and because a shorter disease duration lessens the transmission of infectious *V. cholerae*. Because antibiotics are widely used as part of the cholera treatment regimen, the number of pathogenic *V. cholerae* strains resistant to one or more antibiotics is increasing, as summarized in Table 3. As an environmental organism, *V. cholerae* has the means to acquire resistance genes from intimate contact with intrinsically resistant environmental bacteria (Martínez, 2008) through mobilizable genetic elements. *V. cholerae* can then share these antibiotic resistance genes with other bacteria (Mekalanos *et al.*, 1997; Sedas, 2007); in the human gut, *V. cholerae* may share these resistance traits with commensals or other enteric pathogens, thereby complicating the treatment of an array of infections. To prevent the spread of resistance, it is crucial to limit the use of antibiotics to cholera patients whose lives cannot be saved by rehydration therapies alone.

These circumstances underline the necessity for alternative strategies and novel approaches in managing this disease. A milestone for effective cholera control will be the development of an inexpensive oral vaccine that protects young children from contracting the disease (WHO, 2010). However, in spite of remarkable recent advances in the understanding of the host–pathogen interaction and molecular mechanisms underlying cholera pathogenesis, such a vaccine has yet to be developed (Provenzano *et al.*, 2006).

Prior to the advent of molecular biology and antibiotics, lytic bacteriophages (vibriophages) were employed to control cholera outbreaks in India in the late 1920s and early 1930s (Summers, 1993). Phage therapy should be revisited as *V. cholerae* populations in the environment and human host are naturally controlled by serogroup-specific bacteriophages (Faruque *et al.*, 2005).

Drugs with antisecretory effects have been tested in clinical trials and some have been shown to limit dehydration in cholera patients; aspirin (Islam *et al.*, 1986), berberine (Rabbani *et al.*, 1987), clonidine (Rabbani *et al.*, 1989) and somatostatin (Molla *et al.*, 1984) did not cause a significant reduction in fluid secretion, while indomethacin and nicotinic acid reduced fluid secretion (Van Loon *et al.*, 1992; Rabbani *et al.*, 1983). Inhibitors of CFTR, the molecular target of cholera toxin, show promise as a treatment option. Glycine hydrazide-based inhibitors inhibit fluid loss in a mouse model (Sonawane *et al.*, 2006), and should be tested in clinical trials.

Another promising therapeutic approach entails the development of drugs that disable the bacterium by inhibiting known virulence mechanisms (Hung *et al.*, 2005). Transcriptional activators ToxR, ToxT and TcpP required for the synthesis of cholera toxin and the TCP represent promising targets. As a guiding example, Hung *et al.* (2005) identified a small molecule, virstatin, that protects infant mice from intestinal colonization by *V. cholerae* by inhibiting ToxT. Because such drugs render *V. cholerae* harmless without killing the organism, it has been

Downloaded from www.sgmjournals.org by
IP: 93.91.26.97
On: Sun, 05 Jul 2015 21:04:05

proposed that the lowered selective pressure reduces the frequency of emerging resistant strains (Clatworthy *et al.*, 2007).

The latest research suggests that *V. cholerae* has developed strategies to compete with bacterial neighbours (MacIntyre *et al.*, 2010). MacIntyre and colleagues demonstrated that *V. cholerae* can kill a variety of Gram-negative bacteria including the common intestinal symbiont *E. coli*. If this competition turns out to be essential for *V. cholerae* colonization of the small intestine, therapeutic measures could be developed to disrupt the mechanism(s) employed by these pathogens to outcompete members of the intestinal microflora.

Until new treatment options become available, the provision of safe water sources is the most practical and least expensive approach in fighting the transmission of this devastating disease. Safe water can be used to prepare rehydration solutions on site to save the cost of prepackaged solutions; this would allow the inexpensive treatment of many more patients, as prepackaged solutions are often in short supply, and would reduce the need to administer antibiotics.

In settings with poor sanitation, shed *V. cholerae* reaches the water supply and is transmitted by ingestion of contaminated water. *V. cholerae* strains that spend a longer portion of their life cycle in water between hosts are postulated to display increased toxigenicity compared to those that are transmitted rapidly between hosts (Ewald, 1994). This hypothesis suggests that a change in transmission mode (i.e. through improved sanitation) favours less-toxigenic strains (Ewald, 1994). Further studies are required to determine whether we can manipulate the evolution of *V. cholerae* towards a more benign, less deadly form of disease.

However, until these intriguing and novel approaches in cholera management materialize, we will have to fall back on three key principles in managing this potentially deadly scourge: clean water supplies, containment of cholera patients to stop transmission, and rehydration treatment with use of antibiotics only under life-threatening circumstances.

Acknowledgements

The authors thank Daniele Provenzano (University of Texas Brownsville), Yan Boucher (University of Alberta) and members of the Pukatzki laboratory for helpful discussions. We are grateful to Marcia Craig for critically reviewing the manuscript. S. P. is a recipient of the Alberta Heritage Foundation for Medical Research Scholar Award. Work in S. P.'s laboratory is supported by the Canadian Institute for Health Research Operating Grant MOP-84473, and Alberta Innovates–Health Solutions (funded by the Alberta Heritage Foundation for Medical Research Endowment Fund).

References

Abera, B., Bezabih, B. & Dessie, A. (2010). Antimicrobial susceptibility of *V. cholerae* in north west, Ethiopia. *Ethiop Med J* **48**, 23–28.

Adabi, M., Bakhshi, B., Goudarzi, H., Zahraei, S. M. & Pourshafie, M. R. (2009). Distribution of class I integron and sulfamethoxazole trimethoprim constin in *Vibrio cholerae* isolated from patients in Iran. *Microb Drug Resist* **15**, 179–184.

Allen, J. G., Atherton, F. R., Hall, M. J., Hassall, C. H., Holmes, S. W., Lambert, R. W., Nisbet, L. J. & Ringrose, P. S. (1979). Phosphonopeptides as antibacterial agents: alaphosphin and related phosphonopeptides. *Antimicrob Agents Chemother* **15**, 684–695.

Atherton, F. R., Hall, M. J., Hassall, C. H., Lambert, R. W., Lloyd, W. J. & Ringrose, P. S. (1979). Phosphonopeptides as antibacterial agents: mechanism of action of alaphosphin. *Antimicrob Agents Chemother* **15**, 696–705.

Bani, S., Mastromarino, P. N., Ceccarelli, D., Le Van, A., Salvia, A. M., Ngo Viet, Q. T., Hai, D. H., Bacciu, D., Cappuccinelli, P. & Colombo, M. M. (2007). Molecular characterization of ICEVchVie0 and its disappearance in *Vibrio cholerae* O1 strains isolated in 2003 in Vietnam. *FEMS Microbiol Lett* **266**, 42–48.

Baranwal, S., Dey, K., Ramamurthy, T., Nair, G. B. & Kundu, M. (2002). Role of active efflux in association with target gene mutations in fluoroquinolone resistance in clinical isolates of *Vibrio cholerae*. *Antimicrob Agents Chemother* **46**, 2676–2678.

Beaber, J. W., Hochhut, B. & Waldor, M. K. (2004). SOS response promotes horizontal dissemination of antibiotic resistance genes. *Nature* **427**, 72–74.

Begum, A., Rahman, M. M., Ogawa, W., Mizushima, T., Kuroda, T. & Tsuchiya, T. (2005). Gene cloning and characterization of four MATE family multidrug efflux pumps from *Vibrio cholerae* non-O1. *Microbiol Immunol* **49**, 949–957.

Bina, J. E., Provenzano, D., Wang, C., Bina, X. R. & Mekalanos, J. J. (2006). Characterization of the *Vibrio cholerae vexAB* and *vexCD* efflux systems. *Arch Microbiol* **186**, 171–181.

Bina, X. R., Provenzano, D., Nguyen, N. & Bina, J. E. (2008). *Vibrio cholerae* RND family efflux systems are required for antimicrobial resistance, optimal virulence factor production, and colonization of the infant mouse small intestine. *Infect Immun* **76**, 3595–3605.

Binsztein, N., Costagliola, M. C., Pichel, M., Jurquiza, V., Ramírez, F. C., Akselman, R., Vacchino, M., Huq, A. & Colwell, R. (2004). Viable but nonculturable *Vibrio cholerae* O1 in the aquatic environment of Argentina. *Appl Environ Microbiol* **70**, 7481–7486.

Burrus, V. & Waldor, M. K. (2003). Control of SXT integration and excision. *J Bacteriol* **185**, 5045–5054.

Burrus, V., Marrero, J. & Waldor, M. K. (2006). The current ICE age: biology and evolution of SXT-related integrating conjugative elements. *Plasmid* **55**, 173–183.

Cash, R. A., Music, S. I., Libonati, J. P., Snyder, M. J., Wenzel, R. P. & Hornick, R. B. (1974). Response of man to infection with *Vibrio cholerae*. I. Clinical, serologic, and bacteriologic responses to a known inoculum. *J Infect Dis* **129**, 45–52.

Chander, J., Kaistha, N., Gupta, V., Mehta, M., Singla, N., Deep, A. & Sarkar, B. L. (2009). Epidemiology & antibiograms of *Vibrio cholerae* isolates from a tertiary care hospital in Chandigarh, north India. *Indian J Med Res* **129**, 613–617.

Chandrasekhar, M. R., Krishna, B. V. & Patil, A. B. (2008). Changing characteristics of *Vibrio cholerae*: emergence of multidrug resistance and non-O1, non-O139 serogroups. *Southeast Asian J Trop Med Public Health* **39**, 1092–1097.

Clatworthy, A. E., Pierson, E. & Hung, D. T. (2007). Targeting virulence: a new paradigm for antimicrobial therapy. *Nat Chem Biol* **3**, 541–548.

Colmer, J. A., Fralick, J. A. & Hamood, A. N. (1998). Isolation and characterization of a putative multidrug resistance pump from *Vibrio cholerae*. *Mol Microbiol* **27**, 63–72.

Downloaded from www.sgmjournals.org by
IP: 93.91.26.97
On: Sun, 05 Jul 2015 21:04:05

Colwell, R. R. (1996). Global climate and infectious disease: the cholera paradigm. *Science* **274**, 2025–2031.

Daccord, A., Ceccarelli, D. & Burrus, V. (2010). Integrating conjugative elements of the SXT/R391 family trigger the excision and drive the mobilization of a new class of *Vibrio* genomic islands. *Mol Microbiol* **78**, 576–588.

Dalsgaard, A., Forslund, A., Tam, N. V., Vinh, D. X. & Cam, P. D. (1999). Cholera in Vietnam: changes in genotypes and emergence of class I integrons containing aminoglycoside resistance gene cassettes in *Vibrio cholerae* O1 strains isolated from 1979 to 1996. *J Clin Microbiol* **37**, 734–741.

Das, S., Saha, R. & Kaur, I. R. (2008). Trend of antibiotic resistance of *Vibrio cholerae* strains from East Delhi. *Indian J Med Res* **127**, 478–482.

Dizon, J. J., Fukumi, H., Barua, D., Valera, J., Jayme, F., Gomez, F., Yamamoto, S. I., Wake, A., Gomez, C. Z. & other authors (1967). Studies on cholera carriers. *Bull World Health Organ* **37**, 737–743.

Ehara, M., Nguyen, B. M., Nguyen, D. T., Toma, C., Higa, N. & Iwanaga, M. (2004). Drug susceptibility and its genetic basis in epidemic *Vibrio cholerae* O1 in Vietnam. *Epidemiol Infect* **132**, 595–600.

Ewald, P. W. (1994). *Evolution of Infectious Disease*. Oxford: Oxford University Press.

Faruque, S. M., Albert, M. J. & Mekalanos, J. J. (1998). Epidemiology, genetics, and ecology of toxigenic *Vibrio cholerae*. *Microbiol Mol Biol Rev* **62**, 1301–1314.

Faruque, S. M., Islam, M. J., Ahmad, Q. S., Faruque, A. S., Sack, D. A., Nair, G. B. & Mekalanos, J. J. (2005). Self-limiting nature of seasonal cholera epidemics: role of host-mediated amplification of phage. *Proc Natl Acad Sci U S A* **102**, 6119–6124.

Faruque, S. M., Islam, M. J., Ahmad, Q. S., Biswas, K., Faruque, A. S., Nair, G. B., Sack, R. B., Sack, D. A. & Mekalanos, J. J. (2006). An improved technique for isolation of environmental *Vibrio cholerae* with epidemic potential: monitoring the emergence of a multiple-antibiotic-resistant epidemic strain in Bangladesh. *J Infect Dis* **193**, 1029–1036.

Faruque, A. S., Alam, K., Malek, M. A., Khan, M. G., Ahmed, S., Saha, D., Khan, W. A., Nair, G. B., Salam, M. A. & other authors (2007). Emergence of multidrug-resistant strain of *Vibrio cholerae* O1 in Bangladesh and reversal of their susceptibility to tetracycline after two years. *J Health Popul Nutr* **25**, 241–243.

Garg, P., Sinha, S., Chakraborty, R., Bhattacharya, S. K., Nair, G. B., Ramamurthy, T. & Takeda, Y. (2001). Emergence of fluoroquinolone-resistant strains of *Vibrio cholerae* O1 biotype El Tor among hospitalized patients with cholera in Calcutta, India. *Antimicrob Agents Chemother* **45**, 1605–1606.

Gellert, M., Mizuuchi, K., O'Dea, M. H., Itoh, T. & Tomizawa, J. I. (1977). Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. *Proc Natl Acad Sci U S A* **74**, 4772–4776.

Glass, R. I., Huq, I., Alim, A. R. & Yunus, M. (1980). Emergence of multiply antibiotic-resistant *Vibrio cholerae* in Bangladesh. *J Infect Dis* **142**, 939–942.

Glass, R. I., Huq, M. I., Lee, J. V., Threlfall, E. J., Khan, M. R., Alim, A. R., Rowe, B. & Gross, R. J. (1983). Plasmid-borne multiple drug resistance in *Vibrio cholerae* serogroup O1, biotype El Tor: evidence for a point-source outbreak in Bangladesh. *J Infect Dis* **147**, 204–209.

Goel, A. K., Jain, M., Kumar, P. & Jiang, S. C. (2010). Molecular characterization of *Vibrio cholerae* outbreak strains with altered El Tor biotype from southern India. *World J Microbiol Biotechnol* **26**, 281–287.

Goss, W. A., Deitz, W. H. & Cook, T. M. (1965). Mechanism of action of nalidixic acid on *Escherichia coli*. Inhibition of deoxyribonucleic acid synthesis. *J Bacteriol* **89**, 1068–1074.

Greenough, W. B., III, Gordon, R. S., Jr, Rosenberg, I. S., Davies, B. I. & Benenson, A. S. (1964). Tetracycline in the treatment of cholera. *Lancet* **1**, 355–357.

Guerin, E., Cambray, G., Sanchez-Alberola, N., Campoy, S., Erill, I., Da Re, S., Gonzalez-Zorn, B., Barbé, J., Ploy, M. C. & Mazel, D. (2009). The SOS response controls integron recombination. *Science* **324**, 1034.

Hedges, R. W. & Jacob, A. E. (1975). A 98 megadalton R factor of compatibility group C in a *Vibrio cholerae* El Tor isolate from southern U.S.S.R. *J Gen Microbiol* **89**, 383–386.

Heidelberg, J. F., Eisen, J. A., Nelson, W. C., Clayton, R. A., Gwinn, M. L., Dodson, R. J., Haft, D. H., Hickey, E. K., Peterson, J. D. & other authors (2000). DNA sequence of both chromosomes of the cholera pathogen *Vibrio cholerae*. *Nature* **406**, 477–483.

Herrington, D. A., Hall, R. H., Losonsky, G., Mekalanos, J. J., Taylor, R. K. & Levine, M. M. (1988). Toxin, toxin-coregulated pili, and the toxR regulon are essential for *Vibrio cholerae* pathogenesis in humans. *J Exp Med* **168**, 1487–1492.

Hochhut, B. & Waldor, M. K. (1999). Site-specific integration of the conjugal *Vibrio cholerae* SXT element into *prfC*. *Mol Microbiol* **32**, 99–110.

Hochhut, B., Marrero, J. & Waldor, M. K. (2000). Mobilization of plasmids and chromosomal DNA mediated by the SXT element, a constin found in *Vibrio cholerae* O139. *J Bacteriol* **182**, 2043–2047.

Hochhut, B., Lotfi, Y., Mazel, D., Faruque, S. M., Woodgate, R. & Waldor, M. K. (2001). Molecular analysis of antibiotic resistance gene clusters in *Vibrio cholerae* O139 and O1 SXT constins. *Antimicrob Agents Chemother* **45**, 2991–3000.

Huda, M. N., Chen, J., Morita, Y., Kuroda, T., Mizushima, T. & Tsuchiya, T. (2003). Gene cloning and characterization of VcrM, a Na+-coupled multidrug efflux pump, from *Vibrio cholerae* non-O1. *Microbiol Immunol* **47**, 419–427.

Hung, D. T., Shakhnovich, E. A., Pierson, E. & Mekalanos, J. J. (2005). Small-molecule inhibitor of *Vibrio cholerae* virulence and intestinal colonization. *Science* **310**, 670–674.

Huq, A., Small, E. B., West, P. A., Huq, M. I., Rahman, R. & Colwell, R. R. (1983). Ecological relationships between *Vibrio cholerae* and planktonic crustacean copepods. *Appl Environ Microbiol* **45**, 275–283.

Islam, A., Bardhan, P. K., Islam, M. R. & Rahman, M. (1986). A randomized double blind trial of aspirin versus placebo in cholera and non-cholera diarrhoea. *Trop Geogr Med* **38**, 221–225.

Islam, M. S., Midzi, S. M., Charimari, L., Cravioto, A. & Endtz, H. P. (2009). Susceptibility to fluoroquinolones of *Vibrio cholerae* O1 isolated from diarrheal patients in Zimbabwe. *JAMA* **302**, 2321–2322.

Iwanaga, M., Toma, C., Miyazato, T., Insisiengmay, S., Nakasone, N. & Ehara, M. (2004). Antibiotic resistance conferred by a class I integron and SXT constin in *Vibrio cholerae* O1 strains isolated in Laos. *Antimicrob Agents Chemother* **48**, 2364–2369.

Jabeen, K., Zafar, A. & Hasan, R. (2008). Increased isolation of *Vibrio cholerae* O1 serotype Inaba over serotype Ogawa in Pakistan. *East Mediterr Health J* **14**, 564–570.

Jain, M., Kumar, P., Goel, A. K., Kamboj, D. V. & Singh, L. (2008). Class 1 integrons and SXT elements conferring multidrug resistance in *Vibrio cholerae* O1 strains associated with a recent large cholera outbreak in Orissa, Eastern India. *Int J Antimicrob Agents* **32**, 459–460.

Kaper, J., Lockman, H., Colwell, R. R. & Joseph, S. W. (1979). Ecology, serology, and enterotoxin production of *Vibrio cholerae* in Chesapeake Bay. *Appl Environ Microbiol* **37**, 91–103.

Karki, R., Bhatta, D. R., Malla, S. & Dumre, S. P. (2010). Cholera incidence among patients with diarrhea visiting National Public Health Laboratory, Nepal. *Jpn J Infect Dis* **63**, 185–187.

Downloaded from www.sgmjournals.org by
IP: 93.91.26.97
On: Sun, 05 Jul 2015 21:04:05

Katzung, B. G., Masters, S. B. & Trevor, A. J. (2009). *Basic & Clinical Pharmacology*, 11th edn. New York and London: McGraw-Hill.

Keramat, F., Hashemi, S. H., Mamani, M., Ranjbar, M. & Erfan, H. (2008). Survey of antibiogram tests in cholera patients in the 2005 epidemic in Hamadan, Islamic Republic of Iran. *East Mediterr Health J* **14**, 768–775.

Kim, H. B., Wang, M., Ahmed, S., Park, C. H., LaRocque, R. C., Faruque, A. S., Salam, M. A., Khan, W. A., Qadri, F. & other authors (2010). Transferable quinolone resistance in *Vibrio cholerae*. *Antimicrob Agents Chemother* **54**, 799–803.

Kirn, T. J., Lafferty, M. J., Sandoe, C. M. & Taylor, R. K. (2000). Delineation of pilin domains required for bacterial association into microcolonies and intestinal colonization by *Vibrio cholerae*. *Mol Microbiol* **35**, 896–910.

Krishna, B. V., Patil, A. B. & Chandrasekhar, M. R. (2006). Fluoroquinolone-resistant *Vibrio cholerae* isolated during a cholera outbreak in India. *Trans R Soc Trop Med Hyg* **100**, 224–226.

Lindenbaum, J., Greenough, W. B. & Islam, M. R. (1967). Antibiotic therapy of cholera. *Bull World Health Organ* **36**, 871–883.

MacIntyre, D. L., Miyata, S. T., Kitaoka, M. & Pukatzki, S. (2010). The *Vibrio cholerae* type VI secretion system displays antimicrobial properties. *Proc Natl Acad Sci U S A* **107**, 19520–19524.

Maier, R. A. & Pepper, I. L. (2009). *Environmental Microbiology*, 2nd edn. Amsterdam and London: Elsevier Academic Press.

Mandomando, I., Espasa, M., Vallès, X., Sacarlal, J., Sigaúque, B., Ruiz, J. & Alonso, P. (2007). Antimicrobial resistance of *Vibrio cholerae* O1 serotype Ogawa isolated in Manhiça District Hospital, southern Mozambique. *J Antimicrob Chemother* **60**, 662–664.

Manga, N. M., Ndour, C. T., Diop, S. A., Dia, N. M., Ka-Sall, R., Diop, B. M., Sow, A. I. & Sow, P. S. (2008). Cholera in Senegal from 2004 to 2006: lessons learned from successive outbreaks. *Med Trop (Mars)* **68**, 589–592.

Martínez, J. L. (2008). Antibiotics and antibiotic resistance genes in natural environments. *Science* **321**, 365–367.

Mazel, D. (2006). Integrons: agents of bacterial evolution. *Nat Rev Microbiol* **4**, 608–620.

Mekalanos, J. J., Rubin, E. J. & Waldor, M. K. (1997). Cholera: molecular basis for emergence and pathogenesis. *FEMS Immunol Med Microbiol* **18**, 241–248.

Mhalu, F. S., Mmari, P. W. & Ijumba, J. (1979). Rapid emergence of El Tor *Vibrio cholerae* resistant to antimicrobial agents during first six months of fourth cholera epidemic in Tanzania. *Lancet* **1**, 345–347.

Molla, A. M., Gyr, K., Bardhan, P. K. & Molla, A. (1984). Effect of intravenous somatostatin on stool output in diarrhea due to *Vibrio cholerae*. *Gastroenterology* **87**, 845–847.

Morita, Y., Kodama, K., Shiota, S., Mine, T., Kataoka, A., Mizushima, T. & Tsuchiya, T. (1998). NorM, a putative multidrug efflux protein, of *Vibrio parahaemolyticus* and its homolog in *Escherichia coli*. *Antimicrob Agents Chemother* **42**, 1778–1782.

Ngandjio, A., Tejiokem, M., Wouafo, M., Ndome, I., Yonga, M., Guenole, A., Lemee, L., Quilici, M. L. & Fonkoua, M. C. (2009). Antimicrobial resistance and molecular characterization of *Vibrio cholerae* O1 during the 2004 and 2005 outbreak of cholera in Cameroon. *Foodborne Pathog Dis* **6**, 49–56.

Opintan, J. A., Newman, M. J., Nsiah-Poodoh, O. A. & Okeke, I. N. (2008). *Vibrio cholerae* O1 from Accra, Ghana carrying a class 2 integron and the SXT element. *J Antimicrob Chemother* **62**, 929–933.

Pan, J. C., Ye, R., Wang, H. Q., Xiang, H. Q., Zhang, W., Yu, X. F., Meng, D. M. & He, Z. S. (2008). *Vibrio cholerae* O139 multiple-drug resistance mediated by *Yersinia pestis* pIP1202-like conjugative plasmids. *Antimicrob Agents Chemother* **52**, 3829–3836.

Paulsen, I. T., Brown, M. H. & Skurray, R. A. (1996). Proton-dependent multidrug efflux systems. *Microbiol Rev* **60**, 575–608.

Pierce, N. F., Banwell, J. G., Mitra, R. C., Caranasos, G. J., Keimowitz, R. I., Thomas, J. & Mondal, A. (1968). Controlled comparison of tetracycline and furazolidone in cholera. *BMJ* **3**, 277–280.

Provenzano, D., Kovác, P. & Wade, W. F. (2006). The ABCs (Antibody, B cells, and Carbohydrate epitopes) of cholera immunity: considerations for an improved vaccine. *Microbiol Immunol* **50**, 899–927.

Putman, M., van Veen, H. W. & Konings, W. N. (2000). Molecular properties of bacterial multidrug transporters. *Microbiol Mol Biol Rev* **64**, 672–693.

Rabbani, G. H., Butler, T., Bardhan, P. K. & Islam, A. (1983). Reduction of fluid-loss in cholera by nicotinic acid: a randomised controlled trial. *Lancet* **2**, 1439–1442.

Rabbani, G. H., Butler, T., Knight, J., Sanyal, S. C. & Alam, K. (1987). Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic *Escherichia coli* and *Vibrio cholerae*. *J Infect Dis* **155**, 979–984.

Rabbani, G. H., Butler, T., Patte, D. & Abud, R. L. (1989). Clinical trial of clonidine hydrochloride as an antisecretory agent in cholera. *Gastroenterology* **97**, 321–325.

Rakoto Alson, A. O., Dromigny, J. A., Pfister, P. & Mauclère, P. (2001). *Vibrio cholerae* in Madagascar: study of a multiresistant strain. *Arch Inst Pasteur Madagascar* **67**, 6–13.

Ranjbar, M., Rahmani, E., Nooriamiri, A., Gholami, H., Golmohamadi, A., Barati, H., Rajabifar, D., Barati, S., Sabet, M. S. & other authors (2010). High prevalence of multidrug-resistant strains of *Vibrio cholerae*, in a cholera outbreak in Tehran-Iran, during June-September 2008. *Trop Doct* **40**, 214–216.

Reidl, J. & Klose, K. E. (2002). *Vibrio cholerae* and cholera: out of the water and into the host. *FEMS Microbiol Rev* **26**, 125–139.

Roy, S. K., Islam, A., Ali, R., Islam, K. E., Khan, R. A., Ara, S. H., Saifuddin, N. M. & Fuchs, G. J. (1998). A randomized clinical trial to compare the efficacy of erythromycin, ampicillin and tetracycline for the treatment of cholera in children. *Trans R Soc Trop Med Hyg* **92**, 460–462.

Roychowdhury, A., Pan, A., Dutta, D., Mukhopadhyay, A. K., Ramamurthy, T., Nandy, R. K., Bhattacharya, S. K. & Bhattacharya, M. K. (2008). Emergence of tetracycline-resistant *Vibrio cholerae* O1 serotype Inaba, in Kolkata, India. *Jpn J Infect Dis* **61**, 128–129.

Sack, D. A., Lyke, C., McLaughlin, C. & Suwanvanichkij, V. (2001). Antimicrobial resistance in shigellosis, cholera and campylobacteriosis. WHO Document WHO/CDS/CSR/DRS/2001.8. Geneva: World Health Organization.

Sack, D. A., Sack, R. B., Nair, G. B. & Siddique, A. K. (2004). Cholera. *Lancet* **363**, 223–233.

Safa, A., Nair, G. B. & Kong, R. Y. (2010). Evolution of new variants of *Vibrio cholerae* O1. *Trends Microbiol* **18**, 46–54.

Samal, B., Ghosh, S. K., Mohanty, S. K. & Patnaik, K. (2001). Epidemic of *Vibrio cholerae* serogroup O139 in Berhampur, Orissa. *Indian J Med Res* **114**, 10–11.

Sedas, V. T. (2007). Influence of environmental factors on the presence of *Vibrio cholerae* in the marine environment: a climate link. *J Infect Dev Ctries* **1**, 224–241.

Shimada, T., Arakawa, E., Itoh, K., Okitsu, T., Matsushima, A., Asai, Y., Yamai, S., Nakazato, T., Nair, G. B. & other authors (1994). Extended serotyping scheme for *Vibrio cholerae*. *Curr Microbiol* **28**, 175–178.

Siddique, A. K., Akram, K., Zaman, K., Mutsuddy, P., Eusof, A. & Sack, R. B. (1996). *Vibrio cholerae* O139: how great is the threat of a pandemic? *Trop Med Int Health* **1**, 393–398.

Downloaded from www.sgmjournals.org by
IP: 93.91.26.97
On: Sun, 05 Jul 2015 21:04:05

Singh, A. K., Haldar, R., Mandal, D. & Kundu, M. (2006). Analysis of the topology of *Vibrio cholerae* NorM and identification of amino acid residues involved in norfloxacin resistance. *Antimicrob Agents Chemother* **50**, 3717–3723.

Smith, A. M., Keddy, K. H. & De Wee, L. (2008). Characterization of cholera outbreak isolates from Namibia, December 2006 to February 2007. *Epidemiol Infect* **136**, 1207–1209.

Smith, K. P., Kumar, S. & Varela, M. F. (2009). Identification, cloning, and functional characterization of EmrD-3, a putative multidrug efflux pump of the major facilitator superfamily from *Vibrio cholerae* O395. *Arch Microbiol* **191**, 903–911.

Sonawane, N. D., Hu, J., Muanprasat, C. & Verkman, A. S. (2006). Luminally active, nonabsorbable CFTR inhibitors as potential therapy to reduce intestinal fluid loss in cholera. *FASEB J* **20**, 130–132.

Sugino, A., Peebles, C. L., Kreuzer, K. N. & Cozzarelli, N. R. (1977). Mechanism of action of nalidixic acid: purification of *Escherichia coli nalA* gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. *Proc Natl Acad Sci U S A* **74**, 4767–4771.

Summers, W. C. (1993). Cholera and plague in India: the bacteriophage inquiry of 1927-1936. *J Hist Med Allied Sci* **48**, 275–301.

Taylor, R. K., Miller, V. L., Furlong, D. B. & Mekalanos, J. J. (1987). Use of phoA gene fusions to identify a pilus colonization factor coordinately regulated with cholera toxin. *Proc Natl Acad Sci U S A* **84**, 2833–2837.

Threlfall, E. J. & Rowe, B. (1982). *Vibrio cholerae* El Tor acquires plasmid-encoded resistance to gentamicin. *Lancet* **1**, 42.

Tjaniadi, P., Lesmana, M., Subekti, D., Machpud, N., Komalarini, S., Santoso, W., Simanjuntak, C. H., Punjabi, N., Campbell, J. R. & other authors (2003). Antimicrobial resistance of bacterial pathogens associated with diarrheal patients in Indonesia. *Am J Trop Med Hyg* **68**, 666–670.

Towner, K. J., Pearson, N. J., Mhalu, F. S. & O'Grady, F. (1980). Resistance to antimicrobial agents of *Vibrio cholerae* E1 Tor strains isolated during the fourth cholera epidemic in the United Republic of Tanzania. *Bull World Health Organ* **58**, 747–751.

Van Bambeke, F., Michot, J. M. & Tulkens, P. M. (2003). Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. *J Antimicrob Chemother* **51**, 1067–1077.

Van Loon, F. P., Rabbani, G. H., Bukhave, K. & Rask-Madsen, J. (1992). Indomethacin decreases jejunal fluid secretion in addition to luminal release of prostaglandin E2 in patients with acute cholera. *Gut* **33**, 643–645.

Waldor, M. K., Tschäpe, H. & Mekalanos, J. J. (1996). A new type of conjugative transposon encodes resistance to sulfamethoxazole, trimethoprim, and streptomycin in *Vibrio cholerae* O139. *J Bacteriol* **178**, 4157–4165.

WHO (1995). Meeting on the Potential Role of New Cholera Vaccines in the Prevention and Control of Cholera outbreaks during Acute Emergencies. Document CDR/GPV/95.1. Geneva: World Health Organization.

WHO (2002). New formula oral rehydration salts. *WHO Drug Information* **16**, 121.

WHO (2004). Global Task Force on Cholera Control: first steps for managing an outbreak of acute diarrhoea. Document WHO_CDS_CSR_NCS_2003.7 Rev1. Geneva: World Health Organization.

WHO (2010). High hopes for oral cholera vaccine. *Bull World Health Organ* **88**, 165–166.

Woolley, R. C., Vediyappan, G., Anderson, M., Lackey, M., Ramasubramanian, B., Jiangping, B., Borisova, T., Colmer, J. A., Hamood, A. N. & other authors (2005). Characterization of the *Vibrio cholerae vceCAB* multiple-drug resistance efflux operon in *Escherichia coli*. *J Bacteriol* **187**, 5500–5503.

Downloaded from www.sgmjournals.org by
IP: 93.91.26.97
On: Sun, 05 Jul 2015 21:04:05